CBD Co. Wants Counterclaims Nixed In Epidiolex Patent Row
British pharmaceutical firm GW Pharmaceuticals has urged a New Jersey federal judge to toss counterclaims lodged by InvaGen Pharmaceuticals in a patent dispute regarding GW's flagship CBD-derived epilepsy treatment Epidiolex....To view the full article, register now.
Already a subscriber? Click here to view full article